Fund Gurus

Endologix: Strong Growth Prospects Present Upside

Medical devices and technology companies continue their strong performance of late as investors look ahead to the future of healthcare. We have recently talked about a number of compelling investments in this space, such as Immunogen (NASDAQ:IMGN) and Steris Corp (NYSE:STE). The following article continues the trend and looks at the fast growing company Endologix (NASDAQ:ELGX) with an advanced patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). With over 200,000 people diagnosed in the US each year, ELGX continues to gain market share and has impressive upside capabilities over the medium term offering over 40% upside at current levels.

The Disease

While 200,000 people are diagnosed each year in the US, it...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details